| Grossman, Stuart A |
| Not yet recruiting | 2a | 40 | US | Dichloroacetate | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Food and Drug Administration (FDA) | Glioblastoma | 12/26 | 01/27 | | |
NCT05120284: Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) |
|
|
| Recruiting | 2 | 40 | US | Dichloroacetate (DCA), Sodium Dichloroacetate, Genotype | University of Florida, Food and Drug Administration (FDA) | Glioblastoma Multiforme | 06/25 | 06/25 | | |
BRAF, NCT03973918: Study of Binimetinib With Encorafenib in Adults With Recurrent V600-Mutated HGG |
|
|
| Terminated | 2 | 5 | US | Encorafenib, Braftovi, Binimetinib, Mektovi, Research Bloods, Circulating Tumor DNA, Tumor Tissue | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Pfizer | High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma | 04/22 | 10/23 | | |
NCT05768919: Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas |
|
|
| Recruiting | 1/2 | 30 | US | Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a | SignPath Pharma, Inc., Avance Clinical Pty Ltd. | Glioblastoma | 02/26 | 05/27 | | |
NCT03971734: Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas |
|
|
| Terminated | 1 | 7 | US | Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI) | High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma | 04/22 | 10/23 | | |
NCT03593993: A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas |
|
|
| Terminated | N/A | 3 | US | Surgical Cohort | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Musella Foundation | Glioma, BRAF V600E, Pleomorphic Xantho-Astrocytoma, Glioblastoma | 07/23 | 07/23 | | |
| Eisenberg, David |
| Recruiting | N/A | 656 | US | Ovaprene | Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Contraception | 06/25 | 09/25 | | |
| Baker, Laura |
| Active, not recruiting | N/A | 2000 | US | Self-Guided Lifestyle Intervention, Self-Guided, Structured Lifestyle Intervention | Wake Forest University Health Sciences, Alzheimer's Association | Alzheimer Disease | 07/25 | 07/25 | | |
| Hendrix, Craig |
NCT04686279: Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM) |
|
|
| Completed | 1 | 8 | US | Tenofovir Douche | University of Pennsylvania, University of North Carolina, Chapel Hill, Emory University, Johns Hopkins University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV/AIDS, HIV Prevention | 11/22 | 11/22 | | |
NCT06132386: Analysis of Cellular Kinases and Aging in PBMCs and Colorectal Tissue |
|
|
| Completed | N/A | 18 | US | biopsy | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Aging (NIA) | HIV Infections, Aging | 05/24 | 05/24 | | |
| Wood, Robert |
OUtMATCH, NCT03881696: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants |
|
|
| Active, not recruiting | 3 | 471 | US | Omalizumab, Xolair®, Placebo for Omalizumab, Placebo, Multi-Allergen Oral Immunotherapy, Multi-Allergen OIT, Placebo for Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen OIT, Double-Blind Placebo-Controlled Food Challenge Based Treatment, DBPCFC Based Treatment | National Institute of Allergy and Infectious Diseases (NIAID), Genentech, Inc., Novartis Pharmaceuticals, Rho Federal Systems Division, Inc. | Peanut Allergy, Multi-food Allergy | 03/23 | 06/25 | | |
|
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, Japan, US, RoW | Ligelizumab 120 mg, Ligelizumab 240 mg | Novartis Pharmaceuticals | Food Allergy | 02/25 | 02/25 | | |
NCT03462030: Baked Milk Oral Immunotherapy for Cow's Milk Allergy |
|
|
| Completed | 2 | 41 | US | Baked non-fat cow's milk powder, Investigational New Drug (IND) 17114, Placebo: Tapioca Powder | Johns Hopkins University, Myra Reinhardt Foundation, La Jolla Institute for Allergy & Immunology | Cow's Milk Allergy | 01/21 | 02/24 | | |
| Recruiting | 2 | 72 | Europe, US | remibrutinib, (LOU064), placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Allergy, Peanut | 03/25 | 03/25 | | |
NCT05440643: Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy |
|
|
| Recruiting | 1/2 | 192 | Canada, US | Peanut SLIT-tablet, Placebo | ALK-Abelló A/S, Parexel | Peanut Allergy | 01/26 | 02/26 | | |
| Active, not recruiting | 1/2 | 264 | US, RoW | STMC-103H, Placebo | Siolta Therapeutics, Inc. | Atopic Dermatitis, Type 1 Hypersensitivity | 11/24 | 10/25 | | |
NCT03019328: Early Peanut Introduction: Translation to Clinical Practice |
|
|
| Completed | N/A | 333 | US | Peanut in diet | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID), Massachusetts General Hospital | Peanut Allergy | 10/22 | 03/23 | | |
| Recruiting | N/A | 2500 | US | | National Institute of Allergy and Infectious Diseases (NIAID), Consortium for Food Allergy Research, Rho Federal Systems Division, Inc. | Allergic Diseases, Food Allergy, Atopic Dermatitis | 09/28 | 09/28 | | |
| Acharya, Nisha |
NCT03816397: Adalimumab in JIA-associated Uveitis Stopping Trial |
|
|
| Active, not recruiting | 4 | 118 | Europe, US, RoW | Adalimumab, HUMIRA, Placebo | Nisha Acharya, Children's Hospital of Philadelphia, Children's Hospital Medical Center, Cincinnati, Children's Mercy Hospital Kansas City, National Eye Institute (NEI), Great Ormond Street Hospital for Children NHS Foundation Trust, University Hospitals Bristol and Weston NHS Foundation Trust, Alder Hey Children's NHS Foundation Trust, Newcastle-upon-Tyne Hospitals NHS Trust, Sheffield Children's NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Royal Children's Hospital, Norfolk and Norwich University Hospitals NHS Foundation Trust, Vanderbilt University Medical Center, University of California, Davis, University of Texas at Austin, University of Miami, University Hospitals, Leicester, University of Utah, Colorado Retina Associates, Manchester University NHS Foundation Trust | Uveitis, JIA | 04/25 | 07/25 | | |
| Active, not recruiting | 3 | 222 | Europe, Canada, US, RoW | Adalimumab (ADA), Adalimumab, Humira, Conventional immunosuppression (CON), Azathioprine, Imuran , Cyclosporine, Methotrexate, Rheumatrex, Mycophenolate, CellCept, Cyclosporine, Sandimmune, Neoral, Tacrolimus, Prograf | JHSPH Center for Clinical Trials | Uveitis | 04/24 | 09/24 | | |
| Recruiting | N/A | 140 | US | Calm Health - smartphone application | University of California, San Francisco, Calm.com, Inc. | Non-infectious Uveitis | 08/25 | 08/25 | | |
| Brennan, Daniel C |
NCT05917522: Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation |
|
|
| Recruiting | 2 | 800 | US | Abatacept, Orencia, Standard of Care at US Transplant Centers | National Institute of Allergy and Infectious Diseases (NIAID) | Kidney Transplant | 07/27 | 07/29 | | |
NCT01309022: Immunosuppressive Medications for Participants in ITN005CT (NCT00014911) |
|
|
| No Longer Available | N/A | | US | Sirolimus, Rapamune®, Tacrolimus, Prograf®, Mycophenolate mofetil, MMF, CellCept, Mycophenolic acid, Myfortic® | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN) | Diabetes Mellitus, Type 1 | | | | |
| Recruiting | N/A | 300 | Europe, Canada, US, RoW | MMDx, Prospera, transplant patient blood sample, HLA antibody | University of Alberta, Natera, Inc., One Lambda | Kidney Transplant Rejection | 12/25 | 12/26 | | |
| Recruiting | N/A | 5000 | US | | Wake Forest University Health Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Minority Health and Health Disparities (NIMHD), National Institute of Allergy and Infectious Diseases (NIAID) | Kidney Diseases, Kidney Failure, Kidney Disease, Chronic | 09/24 | 09/24 | | |
KOAR, NCT03326076: Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry |
|
|
| Active, not recruiting | N/A | 4000 | US | Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox) | CareDx | Kidney Transplant Rejection | 06/25 | 12/25 | | |
| Saidha, Shiv |
NCT06167642: Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab |
|
|
| Enrolling by invitation | N/A | 75 | US | Ofatumumab, Kesimpta | Johns Hopkins University, Novartis | Multiple Sclerosis, Tomography, Optical Coherence, Retinal Degeneration, Visual Acuity | 06/25 | 06/25 | | |
NCT05663853: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients |
|
|
| Completed | N/A | 137 | US | | LAPIX Therapeutics Inc. | Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | 04/24 | 04/24 | | |
NCT05442112: Trial of eHealth Wellness Behavioral Interventions and Patient-reported Outcomes |
|
|
| Completed | N/A | 51 | US | Wellness Patient Message | Johns Hopkins University | Multiple Sclerosis | 05/24 | 05/24 | | |
| Brown, Charles |
NCT05308290: Optimizing Cerebral Autoregulation During Surgery |
|
|
| Active, not recruiting | N/A | 77 | US | Blood pressure management according to cerebral autoregulation, Blood pressure management according to usual care | Johns Hopkins University, National Institute on Aging (NIA) | Hip Fractures, Hip Arthropathy, Surgery, Delirium | 06/24 | 06/25 | | |
| Recruiting | N/A | 55 | US | Standard of Care plus Enhanced Patient Education, Motivational Interviewing Intervention, Home-Based Activity Program plus Motivational Interviewing Intervention | Johns Hopkins University, Catalyst Foundation | Aortic Valve Disease, Aortic Valve Replacement | 09/26 | 04/27 | | |
NCT04566172: Preoperative Optimization to Improve Functional Status |
|
|
| Withdrawn | N/A | 100 | US | Inspiratory Muscle Training (IMT), IMT | Johns Hopkins University | Pulmonary Atelectasis, Pneumonia, Ventilator-Associated | 10/26 | 03/27 | | |
| Shoham, Shmuel |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study |
|
|
| Recruiting | 3 | 274 | Europe, US, RoW | DAS181, Placebo, DAS181 COVID-19, DAS181 OL | Ansun Biopharma, Inc. | Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19 | 08/25 | 08/25 | | |
| Completed | 2 | 203 | Europe, US, RoW | Olorofim, F901318 | F2G Biotech GmbH, Iqvia Pty Ltd | Invasive Fungal Infections | 02/23 | 02/23 | | |
| Yarmus, Lonny |
NCT05918783: Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer |
|
|
| Recruiting | 1 | 36 | US | Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, Padeliporfin VTP | Impact Biotech Ltd, Impact biotech Ltd. | Peripheral Lung Tumor | 05/27 | 12/28 | | |
| Enrolling by invitation | N/A | 95 | US | | Johns Hopkins University | Malignant Pleural Effusions | 12/25 | 12/25 | | |
| Recruiting | N/A | 200 | Europe, US | Vacuum-Based IPC, Gravity-Based IPC | Johns Hopkins University, Rocket Medical plc, Swedish Medical Center, Medical University of South Carolina, University of Oxford, Vanderbilt University Medical Center, Northwest Community Healthcare | Pleural Effusion | 12/26 | 12/26 | | |
| Recruiting | N/A | 1200 | US | Observation | Tempus AI, AstraZeneca | Non-Small Cell Lung Cancer | 06/29 | 06/29 | | |
| Recruiting | N/A | 2000 | Canada, US | | Biodesix, Inc. | Nodule Solitary Pulmonary, Non-small Cell Carcinoma | 12/24 | 12/26 | | |
| Enrolling by invitation | N/A | 349 | US | ROSE (presence of cytotech) & liquid prep, NO-ROSE (absence of cytotech) & liquid prep, ROSE (presence of cytotech) & tissue clot sample, NO-ROSE (absence of cytotech) & tissue clot sample | Johns Hopkins University, AstraZeneca | Non-small Cell Lung Cancer (NSCLC) | 12/25 | 03/26 | | |
NCT05257551: Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study |
|
|
| Recruiting | N/A | 50 | US | Observation | Tempus AI, AstraZeneca | Small Cell Lung Cancer | 03/26 | 03/26 | | |
| Bermel, Robert |
NCT05663853: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients |
|
|
| Completed | N/A | 137 | US | | LAPIX Therapeutics Inc. | Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | 04/24 | 04/24 | | |
| Klineova, Sylvia |
NCT05663853: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients |
|
|
| Completed | N/A | 137 | US | | LAPIX Therapeutics Inc. | Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | 04/24 | 04/24 | | |
| Burke, Anne |
| Recruiting | N/A | 656 | US | Ovaprene | Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Contraception | 06/25 | 09/25 | | |
| Rosson, Gedge D |
NCT04533373: Sensory Restoration After DIEP Flap Neurotization |
|
|
| Recruiting | N/A | 156 | US | DIEP Flap Neurotization | Johns Hopkins University, Axogen Corporation | Breast Cancer, Breast Reconstruction, Sensory Restoration | 12/26 | 12/27 | | |
RANGER, NCT01526681: Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction |
|
|
| Recruiting | N/A | 5000 | Europe, Canada, US | Processed Human Nerve Graft, Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc., Autogenous Nerve Graft, Nerve Tube Conduit, Autologous Breast Reconstruction with Neurotization, Autologous Breast Reconstruction without Neurotization | Axogen Corporation | Peripheral Nerve Injuries | 12/25 | 12/25 | | |
| Sullivan, David |
| Active, not recruiting | 3 | 75 | Europe, Canada, Japan, US, RoW | Plozasiran, ARO-APOC3, Placebo | Arrowhead Pharmaceuticals | Familial Chylomicronemia | 04/24 | 04/26 | | |
Gateway, NCT05217667: Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) |
|
|
| Active, not recruiting | 2 | 18 | Canada, US, RoW | ARO-ANG 3 Injection | Arrowhead Pharmaceuticals | Homozygous Familial Hypercholesterolemia | 05/23 | 05/25 | | |
| Gómez, Juan José Cubero |
NCT05383820: Effect of Paracetamol and Ketorolac on RANK-L Levels in Patients Starting Orthodontic Treatment |
|
|
| Recruiting | 4 | 24 | RoW | Ketorolac, Parcetamol | University of Guadalajara | Malocclusion, Pain, Acute | 03/22 | 12/22 | | |
| Recruiting | 3 | 149 | Europe | Multivirus (CMV, EBV, AdV)-specific T cells | Prof. Tobias Feuchtinger, European Commission, Simbec-Orion Group Ltd, Merthyr Tydfil, UK, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany, Leiden University Medical Center, LUMC, Leiden, The Netherlands, Centre Hospitalier Universitaire de Nancy, CHU, Vandoeuvre-Lès-Nancy, France, Ghent University Hospital, UZG, Ghent, Belgium, Ospedale Pediatrico Bambino Gesù, OPBG, Rome, Italy, Newcastle University, UNEW, Newcastle, UK, Vall d'Hebron Institute of Oncology (VHIO) and Banc de Sang I Teixits (BST), Barcelona, Spain | AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications | 06/24 | 12/24 | | |
KEYNOTE-A31, NCT04130542: Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy |
|
|
| Active, not recruiting | 1 | 276 | US | LVGN6051, KEYTRUDA® (pembrolizumab) | Lyvgen Biopharma Holdings Limited, Merck Sharp & Dohme LLC | Cancer | 12/25 | 12/25 | | |
| Completed | N/A | 271 | Europe | Oral nutritional supplement rich in omega-3 and olive oil polyphenols, Physical activity | Endocrinology and Clinical Nutrition Research Center, Spain, Adventia Pharma | Disease-related Malnutrition, Inflammation | 05/24 | 09/24 | | |
| Srikumaran, Uma |
NCT05333211: Ortho-R® for Rotator Cuff Repair Compared With Standard of Care Rotator Cuff Repair Without Ortho-R® |
|
|
| Recruiting | 1/2 | 78 | US | Ortho-R/PRP | ChitogenX Inc, MCRA | Rotator Cuff Tears | 12/23 | 05/24 | | |
ARC, NCT03295994: Operative Versus Non-Operative Treatment for Atraumatic Rotator Cuff Tears |
|
|
| Active, not recruiting | N/A | 189 | US | Operative, Non-Operative | University of Michigan, Patient-Centered Outcomes Research Institute, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Rotator Cuff Tear | 02/25 | 11/26 | | |
NCT06361797: Varying Bone Marrow-Derived Mesenchymal Stem Cells Concentrations' Impact on Rotator Cuff Repair Outcomes |
|
|
| Withdrawn | N/A | 150 | US | Rotator cuff repair augmented with whole bone marrow, Whole bone marrow, Bone marrow aspirate, Rotator cuff repair augmented with concentrated bone marrow, Bone marrow-derived mesenchymal stem cells, Bone marrow concentrate | Johns Hopkins University, ON Foundation | Rotator Cuff Tears | 07/26 | 12/27 | | |
| Leung, Sherry |
NCT04646603: MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients |
|
|
| Recruiting | 2a | 40 | US | MRG-001, Placebo | MedRegen LLC, ICON plc, Johns Hopkins University | COVID-19, ARDS, Human, Stem Cells, Regeneration | 03/22 | 07/22 | | |
NCT01964859: Feasibility Study for Fibroblast Autologous Skin Grafts |
|
|
| Recruiting | 2 | 80 | US | autologous skin fibroblasts | Johns Hopkins University, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), United States Department of Defense | Wounds and Injuries | 12/27 | 11/28 | | |
| Active, not recruiting | 2 | 100 | US | Sulindac 400 MG, Placebo | Duke University, Johns Hopkins University, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | IPMN, IPMN, Pancreatic | 04/26 | 08/26 | | |
NCT04583488: Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis |
|
|
| Terminated | 1 | 2 | US | Intraperitoneal docetaxel, Taxotere | Johns Hopkins University | Peritoneal Carcinomatosis | 08/24 | 08/24 | | |
| Anderson, Thuy |
| Active, not recruiting | N/A | 334 | US | | Harvard School of Public Health (HSPH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Allergy and Infectious Diseases (NIAID), NIH Office of AIDS Research (OAR), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Heart, Lung, and Blood Institute (NHLBI) | HIV/AIDS | 07/25 | 07/25 | | |
| Caplan, Justin |
STEM, NCT04410146: The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma |
|
|
| Completed | N/A | 310 | Europe, US | SQUID Embolization, SQUID Embolization and Surgical Evacuation, Surgical Evacuation, Other: Medical Management | Balt USA, Balt Extrusion, Embo-Flüssigkeiten A.G., AXIOM Real Time Metrics | Subdural Hematoma, Chronic | 02/24 | 05/24 | | |
WEB PAS, NCT04839705: Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device |
|
|
| Recruiting | N/A | 180 | US | WEB | Microvention-Terumo, Inc. | Wide Neck Bifurcation Intracranial Aneurysms | 12/25 | 12/29 | | |
NCT05409989: MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study |
|
|
| Recruiting | N/A | 154 | US | FRED™ X™, Flow Re-Direction Endoluminal Device X | Microvention-Terumo, Inc. | Intracranial Aneurysm | 09/29 | 11/29 | | |
| Wang, Jacqueline M Garonzik |
| Recruiting | N/A | 80 | US | Sub-Normothermic Machine Preservation and Assessment | 34 Lives, PBC, Indiana University Health, University of Miami, MOUNT SINAI HOSPITAL, University of Wisconsin, Madison, Erie County Medical Center, Buffalo, NY, Duke University Hospital, USA | Organ Preservation | 03/25 | 09/25 | | |
PREVENT-HCV, NCT05653232: Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients |
|
|
| Recruiting | N/A | 120 | US | Prophylaxis (P2W), Transmit and Treat (T&T) | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | HCV | 09/25 | 03/27 | | |
| King, Miranda |
NCT04370093: Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss |
|
|
| Recruiting | 4 | 54 | US | Pioglitazone 45 mg, Weight Loss, Pioglitazone + Weight Loss | University of Texas Southwestern Medical Center | Nephrolithiasis, Uric Acid | 06/25 | 07/25 | | |
NCT06481150: A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk. |
|
|
| Recruiting | 4 | 10 | US | Tenapanor, XPHOZAH, IBSRELA, Placebo | University of Texas Southwestern Medical Center, National Center for Advancing Translational Sciences (NCATS) | Hyperoxaluria | 02/25 | 04/25 | | |
NCT05998863: EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy |
|
|
| Recruiting | 3 | 56 | US | EffCaMgCit, Effervescent calcium magnesium citrate, Placebo | University of Texas Southwestern Medical Center | Osteoporosis, Hypomagnesemia | 09/25 | 12/25 | | |
| Ledesma, Jane |
NCT02717156: Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors |
|
|
| Recruiting | 2 | 170 | US | Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, CT, CT SCAN, tomography, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET SCAN, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA | University of Southern California, National Cancer Institute (NCI) | Stage IV Bladder Urothelial Carcinoma, Prostate Cancer, Urothelial Carcinoma | 11/25 | 11/26 | | |
NCI-2012-01247, NCT01684397: Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer |
|
|
| Active, not recruiting | 1/2 | 51 | US | Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Laboratory Biomarker Analysis, Pazopanib Hydrochloride, GW786034B, Votrient, Pharmacological Study | Roswell Park Cancer Institute, GlaxoSmithKline | Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer | 05/25 | 05/25 | | |
NCT06157164: IIT-2022-Simultaneous Urolift™ and Median Lobe Enucleation |
|
|
| Recruiting | N/A | 10 | US | UroLift™ System and Holmium Laser Enucleation of the Prostate (HoLEP) | University of Kansas Medical Center | Benign Prostatic Hyperplasia | 02/25 | 02/25 | | |
| Active, not recruiting | N/A | 196 | US | Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy | Applaud Medical, Inc. | Urinary Stones | 06/23 | 08/24 | | |
NCT06090331: 89Zr-DFO-girentuximab Expanded Access Program (EAP) |
|
|
| Available | N/A | | US | 89Zr-DFO-girentuximab | Telix Pharmaceuticals (Innovations) Pty Limited | Clear Cell Renal Cell Carcinoma | | | | |
| Recruiting | N/A | 100 | US | SOLTIVE Thulium Fiber Laser, Ho:YAG Laser | University of Kansas Medical Center | Kidney Stone | 12/23 | 12/24 | | |
Moses 2, NCT04979143: Moses Vaporization: Is Use of .0 in Holmium Laser Ablation of the Prostate More Efficient |
|
|
| Recruiting | N/A | 124 | US | Surgical Approach | University of Kansas Medical Center, Boston Scientific Corporation | Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | 12/25 | 01/26 | | |
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer |
|
|
| Active, not recruiting | N/A | 572 | US | | University of Washington, Patient-Centered Outcomes Research Institute | Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer | 12/24 | 03/25 | | |
| Not yet recruiting | N/A | 150 | US | ClearPetra Ureteral access sheath | University of Kansas Medical Center | Nephrolithiasis, Kidney Stone | 05/25 | 06/25 | | |
| Recruiting | N/A | 800 | US | | Duke University, Duke Clinical Research Institute, Bristol-Myers Squibb, Exelixis, Merck Sharp & Dohme LLC, Pfizer | Metastatic Renal Cell Carcinoma | 07/26 | 07/26 | | |
| Recruiting | N/A | 4400 | US | Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system | Photocure, Catalyst Pharmaceutical Research | Bladder Cancer | 12/28 | 12/28 | | |
| Kerns, Jennifer |
| Recruiting | N/A | 656 | US | Ovaprene | Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Contraception | 06/25 | 09/25 | | |
| Vaught, Arthur J |
| Completed | 1 | 3 | US | Eculizumab, Soliris | Johns Hopkins University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HELLP Syndrome (HELLP), Third Trimester, Complement Abnormality, Morbidity;Newborn, Maternal Injury, Preeclampsia Severe | 08/23 | 09/23 | | |
| Burley, Tanya |
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD |
|
|
| Recruiting | 3 | 400 | US | TQJ230, pelacarsen, Placebo | Novartis Pharmaceuticals | Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease | 03/27 | 03/27 | | |
| Karakus, Sezen |
NCT04374656: Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic |
|
|
| Completed | N/A | 36 | US | | Johns Hopkins University | Conjunctivitis, SARS-CoV-2, COVID-19, Ocular Infection, Viral, Ocular Inflammation | 05/24 | 05/24 | | |
| Los, Jenna |
| Recruiting | N/A | 25 | US | Automatic Continuous Effusion Shunt implantation, ACES Catheter | Pleural Dynamics, Inc., Medical Metrics Diagnostics, Inc | Pleural Effusion | 06/25 | 12/25 | | |
| Recruiting | N/A | 2000 | Canada, US | | Biodesix, Inc. | Nodule Solitary Pulmonary, Non-small Cell Carcinoma | 12/24 | 12/26 | | |
NCT05257551: Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study |
|
|
| Recruiting | N/A | 50 | US | Observation | Tempus AI, AstraZeneca | Small Cell Lung Cancer | 03/26 | 03/26 | | |
| Centeno, Claire |
| Recruiting | N/A | 2000 | Canada, US | | Biodesix, Inc. | Nodule Solitary Pulmonary, Non-small Cell Carcinoma | 12/24 | 12/26 | | |
| Atta, Mohamed |
| Terminated | 3 | 270 | Europe, Japan, US, RoW | Bardoxolone methyl, RTA 402 | Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc. | Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney | 08/23 | 08/23 | | |
| Terminated | 3 | 667 | Europe, Japan, US, RoW | Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule | Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC | Autosomal Dominant Polycystic Kidney, ADPKD | 08/23 | 08/23 | | |
| Recruiting | 2 | 100 | US, RoW | ANG-3070, Placebo | Angion Biomedica Corp, Angion Biomedica Corp. | Glomerular Disease, Proteinuria | 07/23 | 08/23 | | |
| Completed | N/A | 100 | RoW | Virtual Reality-Enhanced Gagne's Instructional Model | Alexandria University | Acceptance Processes, Rejection, Psychology | 04/23 | 06/23 | | |
| Recruiting | N/A | 160 | RoW | Job Crafting program | Alexandria University | Educational Problems, Work-Related Condition, Nurse's Role | 01/24 | 01/24 | | |
| Completed | N/A | 140 | RoW | Concept Mapping: as a Tool for Problem Based Learning | Alexandria University | Educational Problems, Problem;Learning | 09/23 | 12/23 | | |
| Recruiting | N/A | 140 | RoW | virtual reality Situation-Based Flipped Learning | Alexandria University | Educational Problems, Problem;Learning | 01/24 | 02/24 | | |
mindmenopaus, NCT06421909: Mindfulness-based Educational Intervention on Anxiety, Depression, Stress and Quality of Life on Menopausal Woman |
|
|
| Recruiting | N/A | 120 | RoW | mindfulness-based educational intervention | Alexandria University | Menopause | 06/24 | 08/24 | | |
| Recruiting | N/A | 100 | RoW | motivational Enhancement Therapy | Alexandria University | COPD | 09/24 | 10/24 | | |
| Recruiting | N/A | 120 | RoW | Nurse-Led Heart Math Training Program | Alexandria University | Substance Abuse | 07/24 | 08/24 | | |
| Ged, Yasser |
SOAR, NCT05863351: Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, Study |
|
|
| Recruiting | 3 | 472 | US | Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Questionnaire Administration, Stereotactic Ablative Radiotherapy, SABER, SABR/SBRT, Systemic Therapy | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) | Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | 12/30 | 08/37 | | |
PAPMET2, NCT05411081: Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, Trial |
|
|
| Recruiting | 2 | 200 | US | Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI | National Cancer Institute (NCI) | Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | 07/27 | 07/27 | | |
